Atack CV. (1973). The determination of dopamine by a modification of the dihydroxyindole fluorimetric assay. British journal of pharmacology. 48 [PubMed]
Baba M et al. (1998). Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. The American journal of pathology. 152 [PubMed]
Beal MF. (1996). Mitochondria, free radicals, and neurodegeneration. Current opinion in neurobiology. 6 [PubMed]
Betarbet R et al. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature neuroscience. 3 [PubMed]
Braatz EM, Coleman RA. (2015). A mathematical model of insulin resistance in Parkinson's disease. Computational biology and chemistry. 56 [PubMed]
Bromek E, Haduch A, Gołembiowska K, Daniel WA. (2011). Cytochrome P450 mediates dopamine formation in the brain in vivo. Journal of neurochemistry. 118 [PubMed]
Burré J, Sharma M, Südhof TC. (2015). Definition of a molecular pathway mediating a-synuclein neurotoxicity. The Journal of neuroscience : the official journal of the Society for Neuroscience. 35 [PubMed]
Cardoso SM, Moreira PI, Agostinho P, Pereira C, Oliveira CR. (2005). Neurodegenerative pathways in Parkinson's disease: therapeutic strategies. Current drug targets. CNS and neurological disorders. 4 [PubMed]
Cedillos RO. (2013). a-Synuclein aggregates activate the Nlrp3 inflammasome following vesicle rupture Master's Thesis, 1859. Loyola University. Chicago, IL.
Clayton DF, George JM. (1998). The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends in neurosciences. 21 [PubMed]
Conway KA, Harper JD, Lansbury PT. (1998). Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nature medicine. 4 [PubMed]
Eisenhofer G et al. (1997). Substantial production of dopamine in the human gastrointestinal tract. The Journal of clinical endocrinology and metabolism. 82 [PubMed]
Eliezer D, Kutluay E, Bussell R, Browne G. (2001). Conformational properties of alpha-synuclein in its free and lipid-associated states. Journal of molecular biology. 307 [PubMed]
Eriksen J, Jørgensen TN, Gether U. (2010). Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. Journal of neurochemistry. 113 [PubMed]
Fahn S. (2003). Description of Parkinson's disease as a clinical syndrome. Annals of the New York Academy of Sciences. 991 [PubMed]
Falkenburger BH, Schulz JB. (2006). Limitations of cellular models in Parkinson's disease research. Journal of neural transmission. Supplementum. [PubMed]
Farrer MJ. (2006). Genetics of Parkinson disease: paradigm shifts and future prospects. Nature reviews. Genetics. 7 [PubMed]
Fink AL. (1998). Protein aggregation: Folding aggregates, inclusion bodies and amyloid Fold Des. 3
GREENFIELD JG, BOSANQUET FD. (1953). The brain-stem lesions in Parkinsonism. Journal of neurology, neurosurgery, and psychiatry. 16 [PubMed]
Geddes JW. (2005). alpha-Synuclein: a potent inducer of tau pathology. Experimental neurology. 192 [PubMed]
Gendron TF, Petrucelli L. (2009). The role of tau in neurodegeneration. Molecular neurodegeneration. 4 [PubMed]
Giasson BI et al. (2003). Initiation and synergistic fibrillization of tau and alpha-synuclein. Science (New York, N.Y.). 300 [PubMed]
Hanger DP, Anderton BH, Noble W. (2009). Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends in molecular medicine. 15 [PubMed]
Hiroi T, Imaoka S, Funae Y. (1998). Dopamine formation from tyramine by CYP2D6. Biochemical and biophysical research communications. 249 [PubMed]
Houghton D, Hurtig H. (2013). Parkinson's Disease: Medications.
Iljina M et al. (2016). Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading. Proceedings of the National Academy of Sciences of the United States of America. 113 [PubMed]
Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. (2003). Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. Journal of neuropathology and experimental neurology. 62 [PubMed]
Kahle PJ, Haass C. (2004). How does parkin ligate ubiquitin to Parkinson's disease? EMBO reports. 5 [PubMed]
Kim WS, Kågedal K, Halliday GM. (2014). Alpha-synuclein biology in Lewy body diseases. Alzheimer's research & therapy. 6 [PubMed]
Kitano H, Matsuoka Y, Jouraku A, Funahashi A, Kikuchi N. (2006). Celldesigner: A modeling tool for biochemical networks Proceedings of the 38th Conference on Winter Simulation, Monterey, CA.
LIPKIN LE. (1959). Cytoplasmic inclusions in ganglion cells associated with parkinsonian states: a neurocellular change studied in 53 cases and 206 controls. The American journal of pathology. 35 [PubMed]
Lei P et al. (2010). Tau protein: relevance to Parkinson's disease. The international journal of biochemistry & cell biology. 42 [PubMed]
Levy OA, Malagelada C, Greene LA. (2009). Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis : an international journal on programmed cell death. 14 [PubMed]
Longo GS et al. (2015). Alpha-synuclein A53T mutation is not frequent on a sample of Brazilian Parkinson's disease patients. Arquivos de neuro-psiquiatria. 73 [PubMed]
Lotharius J, Brundin P. (2002). Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nature reviews. Neuroscience. 3 [PubMed]
Marques O, Outeiro TF. (2012). Alpha-synuclein: from secretion to dysfunction and death. Cell death & disease. 3 [PubMed]
Masters JM, Noyce AJ, Warner TT, Giovannoni G, Proctor GB. (2015). Elevated salivary protein in Parkinson's disease and salivary DJ-1 as a potential marker of disease severity. Parkinsonism & related disorders. 21 [PubMed]
Meiser J, Weindl D, Hiller K. (2013). Complexity of dopamine metabolism. Cell communication and signaling : CCS. 11 [PubMed]
Mellick GD et al. (2009). Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. Parkinsonism & related disorders. 15 [PubMed]
Oczkowska A, Lianeri M, Kozubski W, Dorszewska J. (2014). Mutations of PARK genes and a-synuclein and Parkin concentrations in Parkinson's disease A Synopsis of Parkinson's Disease.
Parkinson J. (2002). An essay on the shaking palsy. 1817. The Journal of neuropsychiatry and clinical neurosciences. 14 [PubMed]
Perez RG et al. (2002). A role for alpha-synuclein in the regulation of dopamine biosynthesis. The Journal of neuroscience : the official journal of the Society for Neuroscience. 22 [PubMed]
Ramanan VK, Saykin AJ. (2013). Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. American journal of neurodegenerative disease. 2 [PubMed]
Rao RV, Bredesen DE. (2004). Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. Current opinion in cell biology. 16 [PubMed]
Sahay S et al. (2015). Familial Parkinson disease-associated mutations alter the site-specific microenvironment and dynamics of a-synuclein. The Journal of biological chemistry. 290 [PubMed]
Sass MB, Lorenz AN, Green RL, Coleman RA. (2009). A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease. Journal of neuroscience methods. 178 [PubMed]
Sato S, Cerny RL, Buescher JL, Ikezu T. (2006). Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. Journal of neurochemistry. 98 [PubMed]
Schapira AH. (2008). Mitochondria in the aetiology and pathogenesis of Parkinson's disease. The Lancet. Neurology. 7 [PubMed]
Schapira AH et al. (1990). Mitochondrial complex I deficiency in Parkinson's disease. Journal of neurochemistry. 54 [PubMed]
Sharpless NS et al. (1981). Free and conjugated dopamine in human ventricular fluid. Brain research. 217 [PubMed]
Shulman JM, De Jager PL, Feany MB. (2011). Parkinson's disease: genetics and pathogenesis. Annual review of pathology. 6 [PubMed]
Sidhu A, Wersinger C, Moussa CE, Vernier P. (2004). The role of alpha-synuclein in both neuroprotection and neurodegeneration. Annals of the New York Academy of Sciences. 1035 [PubMed]
Singh Dolt K, Hammachi F, Kunath T. (2017). Modeling Parkinson's disease with induced pluripotent stem cells harboring a-synuclein mutations. Brain pathology (Zurich, Switzerland). 27 [PubMed]
Sipos I, Tretter L, Adam-Vizi V. (2003). Quantitative relationship between inhibition of respiratory complexes and formation of reactive oxygen species in isolated nerve terminals. Journal of neurochemistry. 84 [PubMed]
Speed NK. (2010). The role of insulin signaling on dopamine transporter trafficking. Doctoral dissertation, Vanderbitt University, Nashville, TN.
Sulzer D. (2001). alpha-synuclein and cytosolic dopamine: stabilizing a bad situation. Nature medicine. 7 [PubMed]
Tretter L, Adam-Vizi V. (2004). Generation of reactive oxygen species in the reaction catalyzed by alpha-ketoglutarate dehydrogenase. The Journal of neuroscience : the official journal of the Society for Neuroscience. 24 [PubMed]
Wellstead P, Cloutier M. (2009). A systems approach to Parkinson's disease.
Wenya W. (2011). Inhibition of Tau phosphorylation as a potential strategy in treatment of Parkinson's disease Towards New Therapies for Parkinson's Disease.
Werner-Allen JW, DuMond JF, Levine RL, Bax A. (2016). Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of a-Synuclein. Angewandte Chemie (International ed. in English). 55 [PubMed]
Wersinger C, Prou D, Vernier P, Niznik HB, Sidhu A. (2003). Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity. Molecular and cellular neurosciences. 24 [PubMed]
Wersinger C, Sidhu A. (2003). Attenuation of dopamine transporter activity by alpha-synuclein. Neuroscience letters. 340 [PubMed]
Yamamori H et al. (2007). Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification. Neuroscience letters. 418 [PubMed]
Yeager MP, Coleman RA. (2010). In silico evidence for glutathione- and iron-related pathogeneses in Parkinson's disease. Journal of neuroscience methods. 188 [PubMed]
Zhang Y et al. (2000). Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proceedings of the National Academy of Sciences of the United States of America. 97 [PubMed]
Sasidharakurup H, Nair L, Bhaskar K, Diwakar S. (2019). Computational Modelling of TNFa Pathway in Parkinson’s Disease – A Systemic Perspective Complex Networks and Their Applications VIII. COMPLEX NETWORKS 2019. Studies in Computational Intell. 882